Sidra Medicine Becomes First Hospital in Qatar to Offer CRISPR Gene Therapy for Sickle Cell Disease and Thalassemia
核心洞察
Sidra Medicine has been qualified by Vertex Pharmaceuticals to administer Casgevy, the world's first approved CRISPR/Cas9 (搜索) gene therapy, making it the first hospital in Qatar to offer this treatment.
The therapy is available for patients aged 12 years and older with transfusion-dependent beta thalassemia (搜索) and severe sickle cell disease (搜索), offering potential functional cure through one-time treatment.
Sidra Medicine currently follows approximately 150 to 200 children in Qatar diagnosed with thalassemia (搜索) and sickle cell disease (搜索), with the therapy reserved for the most severe cases.
Sidra Medicine, a member of Qatar Foundation (搜索), has achieved a historic milestone by becoming the first hospital in Qatar qualified to administer Casgevy, a groundbreaking CRISPR/Cas9 (搜索)-based gene therapy treatment. The hospital was selected by Vertex Pharmaceuticals as one of a limited number of hospitals worldwide authorized to deliver this revolutionary treatment for patients aged 12 years and older living with transfusion-dependent beta thalassemia (搜索) (TDT) and severe sickle cell disease (搜索) (SCD).
First-in-Class CRISPR Therapy Arrives in Qatar
Casgevy represents the world's first approved medicine utilizing Nobel Prize-winning CRISPR/Cas9 (搜索) technology to treat inherited blood disorders. The therapy has received approval from Qatar's Ministry of Public Health (MOPH), the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other regulatory agencies worldwide.
"We are proud to be chosen as the first hospital in Qatar to deliver a gene editing therapy with the potential for a functional cure," said Prof. Ibrahim Janahi, Chief Medical Officer at Sidra Medicine. "This milestone reinforces Qatar's position as a regional leader in advanced medicine and precision health."
The therapy targets the genetic root cause of these inherited blood disorders and has demonstrated transformative outcomes for patients with sickle cell disease (搜索) and independence from regular blood transfusions for patients with transfusion-dependent beta thalassemia (搜索).
Addressing Critical Patient Need
Sidra Medicine currently follows approximately 150 to 200 children in Qatar diagnosed with thalassemia (搜索) and sickle cell disease (搜索). While not all patients require gene therapy, Casgevy is specifically reserved for those with the most severe forms of SCD or TDT—patients who continue experiencing frequent pain crises, stroke risk, or the cumulative burden of lifelong transfusions despite receiving the best available medical care.
"For this group, where conventional treatment is no longer enough, Casgevy offers something genuinely new: a one-time intervention aimed at the root cause," according to the hospital's announcement.
Dr. Chiara Cugno, Acting Chief of Pediatric Hematology, Oncology and Bone Marrow Transplant and Director of the Advanced Cell Therapy Core at Sidra Medicine, emphasized the historic significance: "The introduction of Casgevy marks a historic advancement for people living with transfusion-dependent beta thalassemia (搜索) and severe sickle cell disease (搜索). This therapy offers not only hope but the potential for a functional cure, by addressing these diseases at their genetic origin."
Complex Treatment Process
The treatment journey involves a highly specialized multi-step process. It begins with the safe collection of a patient's stem cells through apheresis. In collaboration with Vertex, these cells are sent to expert laboratories where they undergo gene editing and validation using CRISPR/Cas9 (搜索) technology. Once edited, the cells are returned to Sidra Medicine and preserved until infusion.
Before receiving the gene-edited cells, patients undergo chemotherapy to prepare their bodies to accept the new cells. The modified cells are then infused back into the patient, where they begin growing in the bone marrow and start producing healthy red blood cells. This process is followed by comprehensive post-treatment recovery and long-term monitoring led by Sidra Medicine's multidisciplinary team.
Regional Leadership in Precision Medicine
Hisham Hagar, Executive Country Manager at Vertex GCC, highlighted the significance of this partnership: "The launch of the CRISPR/Cas9 (搜索) therapy in Qatar represents a significant leap forward in our efforts against serious diseases. This achievement is a direct result of our invaluable partnership with Sidra Medicine and reinforces Vertex's mission to transform lives through scientific innovation."
Prof. Khalid Fakhro, Chief Research Officer at Sidra Medicine, positioned this development within Qatar's broader precision health vision: "This milestone exemplifies our precision health vision, where treatment is guided by each patient's unique genetic makeup. By bringing transformative gene therapies like Casgevy to Qatar, Sidra Medicine is leveraging cutting-edge research and clinical practice to deliver personalized care for children living with rare and inherited diseases."
The hospital has already onboarded its first patient who is currently undergoing assessment for the therapy. Casgevy has been successfully administered to patients globally outside of clinical trials, achieving transfusion independence and significant improvements in quality of life.
This milestone reinforces Sidra Medicine's vision to become a regional center of excellence in pediatric cell and gene therapy, expanding access to advanced, personalized, and life-changing treatments for patients in Qatar and the broader MENA region.